SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), is thrilled to announce the Maryland Tech Council (MTC), one of the largest technology and life science trade associations in the U.S., has selected Frank Amato, CEO and president, Maryland-headquartered SDx, as the 2023 Life Sciences CEO of the Year at the ICON Awards.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230502005209/en/
(Photo: Business Wire)
“I’m deeply gratified with this recognition and honored to be among the top technology and life sciences executives in Maryland,” says Amato. “This award reflects the hard work and accomplishments of the entire SDx team in advancing our goal to educate patients, families and payers on the importance of early detection of AD, encourage lifestyle strategies to prevent cognitive decline and raise awareness on the value of our DISCERN™ test, the first highly accurate, minimally invasive test supporting a clinician’s diagnosis of AD versus other forms of dementia.”
The MTC selected Amato based upon his performance as an outstanding leader and communicator, making service an integral component of the Company’s growth and profitability and demonstrated ability to take calculated risks that lead to success.
“DISCERN is recognized as an important breakthrough for the AD community because there are currently no other autopsy-validated tests that are highly sensitive and highly specific for identifying AD in people recently diagnosed with dementia or mixed-dementia,” continues Amato. “AD is complex but diagnosing it doesn’t have to be. DISCERN provides a definitive diagnosis of AD even in the community setting which is more readily accessible and time- and cost-effective.”
Dr. Daniel Alkon, chief scientific advisor, SDx, an early pioneer of the SDx diagnostic technology and a finalist in the C-Suite category of the ICON Awards, says, “Frank’s work as a distinguished leader in the life science community ensures that SDx will remain at the forefront of AD innovation. He has assembled a diverse team of passionate and experienced lab technicians, knowledgeable business advisory council members and experienced scientific and medical advisors. His work brings greater awareness of AD among providers, payers and patients and helps all stakeholders to better recognize the symptoms of AD and understand the importance of an accurate diagnosis.”
About SYNAPS Dx
SYNAPS Dx is a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD). The Company offers DISCERN™, the first highly accurate, minimally invasive test supporting a clinician’s definitive diagnosis of AD versus other forms of dementia, even in people recently diagnosed with dementia. SYNAPS Dx’s laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing. Physicians and patients seeking more information can visit https://discerntest.com/. For more information on the Company, visit https://www.synapsdx.com/. Contact: info@synapsdx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230502005209/en/
Contacts
Media:
Caroline Chambers
CPR Communications
cchambers@cpronline.com
201.641.1911 x 21
